T1	Participants 603 725	Patients who met remission criteria at 2 consecutive weekly visits during 6 to 12 weeks of open-label olanzapine treatment
T2	Participants 486 601	patients presenting with a mixed index episode who were enrolled in a larger double-blind, placebo-controlled trial
